仁和药业(000650) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was CNY 1,241,563,948.74, representing a 17.28% increase compared to CNY 1,058,621,400.55 in the same period last year[4] - Net profit attributable to shareholders for Q3 2021 reached CNY 192,287,663.67, a 45.32% increase from CNY 132,316,589.63 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 172,807,310.59, up 31.68% from CNY 131,229,387.59 year-on-year[4] - Operating profit increased by 35.96% to CNY 789,078,770.27, driven by higher sales and reduced period expenses[11] - The net profit for the third quarter of 2021 was approximately ¥627.20 million, an increase of 40.7% compared to ¥445.92 million in the same period last year[35] - The operating profit reached ¥789.08 million, up from ¥580.39 million, reflecting a growth of 35.9% year-over-year[35] - The total comprehensive income for the quarter was approximately ¥627.20 million, compared to ¥445.92 million in the same period last year, reflecting an increase of 40.7%[36] Assets and Liabilities - The company's total assets at the end of Q3 2021 were CNY 6,738,669,624.29, reflecting a 5.83% increase from the previous year's adjusted total of CNY 6,367,743,911.80[6] - The company's total liabilities increased to RMB 1,138,762,197.00 from RMB 728,437,041.77, representing a growth of approximately 56%[26] - The total assets as of September 30, 2021, amounted to RMB 6,738,669,624.29, compared to RMB 6,367,743,911.80 at the end of 2020, reflecting an increase of about 5.8%[29] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 279,514,617.22, down 18.25% from CNY 341,931,019.64 in the previous year[4] - The cash flow from operating activities generated a net cash inflow of ¥279.51 million, down from ¥341.93 million in the previous year, indicating a decrease of 18.3%[40] - The company reported a significant increase in investment cash inflows, totaling approximately ¥7.68 billion, compared to ¥4.12 billion in the previous year, an increase of 86.5%[40] - The net cash flow from investing activities was negative at approximately -¥229.85 million, contrasting with a positive inflow of ¥659.22 million in the previous year[40] Earnings Per Share - The company's basic earnings per share for Q3 2021 was CNY 0.1373, a 28.56% increase from CNY 0.1068 in the same period last year[4] - Basic earnings per share for the quarter were ¥0.3748, compared to ¥0.3064 in the same quarter last year, representing a growth of 22.2%[36] Investments and Acquisitions - The company acquired 80% equity in seven companies for a total of RMB 719.496 million, completed by the end of July 2021[19] - Cash paid for investments rose by 112.99% to CNY 7,065,756,742.14, due to increased purchases of financial products[11] Other Financial Metrics - The weighted average return on equity for Q3 2021 was 3.65%, an increase from 3.31% in the same period last year[4] - Research and development expenses rose by 60.11% to CNY 42,760,585.61, reflecting increased investment in new product development[11] - Accounts receivable increased by 173.44% to CNY 866,303,171.38, attributed to increased sales and credit sales[8] - Tax payable increased by 84.22% to CNY 241,708,121.91, primarily due to increased sales and deferred tax liabilities[11]